Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00317668
Recruitment Status : Unknown
Verified April 2006 by Hadassah Medical Organization. Recruitment status was: Recruiting
The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
120 epilepsy patients from the epilepsy clinic and Emergency Room (ER)
Controls: 100 patients with other neurological diseases and no epilepsy; and 30 healthy volunteers.